Form 4: BridgeBio Pharma Director Eric Aguiar Receives Significant Equity Compensation Grant

BridgeBio Pharma, Inc. director Eric Aguiar was granted 6,589 restricted stock units and options to purchase 8,425 shares of common stock, vesting over three years.

Summary

• Eric Aguiar, a Director at BridgeBio Pharma, Inc. (BBIO), received an equity compensation grant on June 20, 2025.
• The grant includes 6,589 Restricted Stock Units (RSUs) and stock options for 8,425 shares of common stock.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
• The stock options have an exercise price of $41.73 per share and an expiration date of June 19, 2035.
• Both the RSUs and stock options will vest over a three-year period, with one-third vesting each year after June 20, 2025.
• Full vesting for both grants is scheduled for June 20, 2028, contingent upon Mr. Aguiar's continued service on the Issuer's board of directors.

Sentiment

Score: 7

Explanation: The grant of equity compensation to a director is a positive development as it aligns the director's interests with those of the shareholders, promoting long-term commitment and performance. It is a standard practice and does not indicate any negative operational or financial issues.

Positives

• The grant of equity compensation to Director Eric Aguiar aligns his financial interests with those of the company's shareholders, promoting long-term value creation.
• Equity compensation is a standard and effective practice for attracting, retaining, and incentivizing key board members.

Risks

• The vesting of both the restricted stock units and stock options is contingent upon Eric Aguiar's continued service on BridgeBio Pharma's board of directors until June 20, 2028.

Future Outlook

The vesting schedule for the granted equity compensation indicates a commitment from Director Eric Aguiar to continue his service on the board of directors until at least June 20, 2028, aligning his long-term interests with the company's performance.

Industry Context

The grant of restricted stock units and stock options to a director is a common and standard practice within the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract, retain, and incentivize board members by aligning their financial success with the long-term performance of the company.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess the compensation against global benchmarks. However, equity compensation for directors, including RSUs and stock options with multi-year vesting, is a widely adopted practice across the biotech and broader corporate sectors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially fostering decisions that enhance long-term shareholder value.

Next Steps

• Continued service of Eric Aguiar on the BridgeBio Pharma, Inc. board of directors to fulfill vesting conditions for the equity grants.

Key Dates

Recommendation

Keywords

BridgeBio Pharma, BBIO, SEC Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Eric Aguiar